{"entity":{"id":"nct02050321","kind":"trial","name":"A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma","aka":[],"tldr":"A phase 2 trial of Acitretin and Vemurafenib in Melanoma, run by University of Arizona, recorded as terminated on the registry.","summary":"A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma is a phase 2 interventional study registered as NCT02050321 by University of Arizona, with 2 participants recorded, started 2013-12 and due to reach its primary completion in 2014-12. Interventions recorded: Acitretin, Vemurafenib. Conditions recorded: Malignant Melanoma.\n\nLinked to the drug Acitretin because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02050321","url":"https://clinicaltrials.gov/study/NCT02050321"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["acitretin","vemurafenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02050321","phase":"2","setting":"A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma","sponsor":"University of Arizona","enrolled":2,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02050321/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"acitretin","kind":"drug","name":"Acitretin","route":"/drugs/acitretin/"},{"id":"vemurafenib","kind":"drug","name":"Vemurafenib","route":"/drugs/vemurafenib/"}]}}